- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06054880
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency
An Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Efficacy, and Physician Satisfaction of Two Different Doses of Bludigo™ (Indigotindisulfonate Sodium Injection, USP) 0.8% When Used as an Aid in the Determination of Ureteral Patency
This is a randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Bludigo™ (indigotindisulfonate Sodium Injection, USP) 0.8% when used as an aid in the determination of ureteral patency.
Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure, age 18 to 85 years inclusive, will be screened for participation. Screening will occur within 30 days before study drug administration (Day of Surgery). After signing the informed consent, review of inclusion and exclusion criteria will be performed, the collection of concomitant medications, medical history, physical examination, baseline laboratory testing, 12-lead ECG, and vital sign measurements will be completed during the screening visit.
On the day of surgery (Day 1) subjects will be evaluated for eligibility for randomization. Eligible subjects will be stratified by BMI (<30.0 kg/m2or ≥ 30.0 kg/m2) and randomized in a 1:1 ratio to receive a dose of either Bludigo™ high dose (5.0 mL) or Bludigo™ low dose (2.5 mL). Each randomized subject will serve as his/her own control (i.e., intra-patient controlled) by receiving a dose of normal saline prior to receiving the randomized Bludigo™ dose.
All treated subjects will have a follow-up visit 7 to 30 days (± 2 days) after the procedure. A final telephone follow-up call will occur on Day 30 (± 2 days) in subjects who have the follow-up visit before Day 28. Safety assessments will include monitoring of AEs during and post the procedure, clinical laboratory tests, 12-Lead ECG, and vital sign measurements.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Michelle Boytim, P.hD.
- Phone Number: 610-850-7115
- Email: michelle.boytim@provepharm.com
Study Locations
-
-
New York
-
Albany, New York, United States, 12008
- Recruiting
- Albany Medical Center
-
Contact:
- Mark White, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects between ≥ 18 and ≤ 85 years old
- Subjects who signed a written IRB approved, informed consent form
- Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure
Exclusion Criteria:
- Subjects with stage 4 or 5 Chronic Kidney Failure as evidenced by a GFR <30 mL/min (calculated using the MDRD formula and standardized by using individual's body surface area) or need for dialysis in the near future, or having only 1 kidney
- Subjects with known severe hypersensitivity reactions to Bludigo™ or other dyes, including contrast dyes
- Known history of drug or alcohol abuse within 6 months prior to the time of screening visit
- Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g. major systemic diseases)
- Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures
- Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
- Subjects with life expectancy < 6 months
- Requirement for concomitant treatment that could bias primary evaluation.
- Subjects who are pregnant or breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Saline
116 subjects treated with 5 ml of saline then crossover to treatment arm
|
Placebo
|
Experimental: High Dose
58 subjects randomly treated with 5 mL of drug
|
Placebo
Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
Other Names:
|
Experimental: Low Dose
58 subjects randomly treated with 2.5 mL of drug
|
Placebo
Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Paired sample difference (Bludigo™-Saline) in urine jet conspicuity score .
Time Frame: 10 minutes post study drug administration
|
Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows:
Paired sample difference (Bludigo™-Saline) in conspicuity score (PSDCS). PSDCS will be calculated for each ureter (left or right) for each subject from each reviewer. |
10 minutes post study drug administration
|
Responders to Bludigo
Time Frame: 10 Minutes post study drug administration
|
Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows:
A subject is considered a responder to Bludigo™ if there is >=1 point improvement in the conspicuity score following the Bludigo™- treatment vs the saline treatment and the conspicuity score for the Bludigo™ treatment must be (3, 4, or 5). The responder criteria will be assessed separately for each ureter (left or right) from each reviewer. |
10 Minutes post study drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events and serious adverse events.
Time Frame: 30 days post study drug administration
|
Percentage of patients in each treatment group who experience an adverse event post treatment
|
30 days post study drug administration
|
Changes in clinical safety laboratory values
Time Frame: 30 days post study drug administration
|
Proportion of subjects with clinically important changes in clinical safety laboratory tests after treatment
|
30 days post study drug administration
|
Changes in vital signs post treatment
Time Frame: 30 days post study drug administration
|
Proportion of subjects with clinically important changes in vital signs after treatment
|
30 days post study drug administration
|
Changes in ECG post treatment
Time Frame: 30 days post study drug administration
|
Proportion of subjects with clinically important changes in ECGs after treatment
|
30 days post study drug administration
|
Changes in blood pressure by dose group and BMI (kg/m^2)
Time Frame: 30 days post study drug administration
|
Comparison of post treatment changes in blood pressure by dose group and BMI (kg/m^2)
|
30 days post study drug administration
|
Changes in heart rate by dose group and BMI (kg/m^2)
Time Frame: 30 days post study drug administration
|
Comparison of post treatment changes in heart rate by dose group and BMI (kg/m^2)
|
30 days post study drug administration
|
Changes in pulse oximetry by dose group and BMI (kg/m^2)
Time Frame: 30 days post study drug administration
|
Comparison of post treatment changes in pulse oximetry by dose group and BMI (kg/m^2)
|
30 days post study drug administration
|
Physician Satisfaction
Time Frame: 10 Minutes post study drug administration
|
To determine physicians' overall satisfaction with the Bludigo™ treatment by assessing the proportion of surgeons who agree using the 5-point Physician Satisfaction Agreement Scale (PSAS) with the statement: "Compared to the saline treatment, my ability to assess ureter patency was improved after the addition of Bludigo™."
|
10 Minutes post study drug administration
|
Time to visualization
Time Frame: 10 minutes post study drug administration
|
To describe the time to visualization (TTV) of blue color in the ureteral jets flow following Bludigo™ treatment
|
10 minutes post study drug administration
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PVP-22IC04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ureter Injury
-
Prove pharmCompletedUreter InjuryUnited States
-
Intuitive SurgicalNot yet recruiting
-
Intuitive SurgicalCompletedUreter InjuryUnited States
-
Oxford University Hospitals NHS TrustUniversity of OxfordCompleted
-
Li-Cor, Inc.CompletedIntraoperative Ureter InjuryUnited States
-
Intuitive SurgicalRecruitingA Safety and Feasibility Study of IS-001 Injection in Patients Undergoing Robotic Colorectal SurgeryUreter InjuryUnited States
-
Li-Cor, Inc.WithdrawnIntraoperative Ureter InjuryUnited States
-
Cecilia CalvoThe Cleveland ClinicCompleted
-
Curadel Surgical Innovations, Inc.Leiden University Medical CenterNot yet recruitingInjury of Ureter During Surgery (Disorder)
-
Tepecik Training and Research HospitalRecruitingComplication of Surgical Procedure | Surgical Injury | Bladder Injury | Ureter InjuryTurkey
Clinical Trials on Saline injection 0.9%
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Green Valley Group of ChinaUnknown
-
MiMedx Group, Inc.Completed
-
MiMedx Group, Inc.CompletedTendonitis;AchillesUnited States
-
Jeffrey Alan Klein, MDNot yet recruitingAnesthesia, Local | Injection Site Irritation | Injection Site Discomfort | Injection Site Bruising | Benzoic Acid Adverse ReactionUnited States
-
Prove pharmRecruiting
-
MiMedx Group, Inc.CompletedFasciitis, PlantarUnited States
-
University of New MexicoCompleted
-
Arrowhead PharmaceuticalsCompletedNon-alcoholic SteatohepatitisNew Zealand
-
Arrowhead PharmaceuticalsCompletedHepatitis BAustralia, Hong Kong, New Zealand